Table 3.
Results of representative RCT for chemoprevention of CRC
| Study | Events/evaluated | Results | Adverse events | |
|---|---|---|---|---|
| Treatment | Control | |||
| Sturmer21 | NA | NA | Negative (RR, 1.07; 95% CI, 0.75‐1.53) | Various gastrointestinal symptoms and diseases |
| Cook20 | 133/19 934 | 136/19 942 | Negative (RR, 0.97; 95% CI, 0.77‐1.24) | Not reported |
| aBenamouzig24 | 42/102 | 33/83 | Negative (RR, 0.96; 95% CI, 0.75‐1.22) | Insignificant difference |
| aLogan25 | 99/434 | 121/419 | Positive (RR, 0.79; 95% CI, 0.63‐0.99) | Insignificant difference |
| aIshikawa22 | 56/152 | 73/159 | Positive (RR, 0.60; 95% CI, 0.36‐0.98) | No serious adverse effects |
| aSandler26 | 43/259 | 70/258 | Positive (RR, 0.65; 95% CI, 0.46‐0.91) | Insignificant difference |
| aBaron23 | 300/721 | 171/363 | Positive with aspirin, 81 mg (RR, 0.81; 95% CI, 0.69‐0.96) | Insignificant difference |
| aArber14 | 95/589 | 83/334 | Positive (RR, 0.64; 95% CI, 0.56‐0.75) | Insignificant increase in cardiovascular events (RR, 1.30; 95% CI, 0.65‐2.62) |
| aBaron,15 Bresalier17 | 460/1158 | 646/1218 | Positive (RR, 0.76; 95% CI, 0.57‐0.83) | Increased cardiovascular events (HR, 1.92; 95% CI, 1.19‐3.11) |
| aBertagnolli,16 Solomon18 | 548/1356 | 421/679 | Positive for both doses (RR, 0.67 and 0.55; 95% CI, 0.59‐0.77 and 0.48‐0.64) | Increased death from cardiovascular causes (HR, 2.3 and 3.4; 95% CI, 0.9‐5.5 and 1.4‐7.8) |
| aHigurashi27 | 22/71 | 32/62 | Positive (RR, 0.60; 95% CI, 0.39‐0.92) | No serious adverse events |
| aTokudome28 | 56/96 | 54/85 | Negative (RR, 0.81; 95% CI 0.54‐1.21) | No adverse events |
| aBonithon‐Kopp29 | 28/176 | 36/178 | Negative (RR, 0.66; 95% CI, 0.38‐1.17) | More frequent side‐effects (26/176 vs 12/178; P = .043) |
| aBaron30 | 33/459 | 24/454 | Positive (RR, 0.85; 95% CI, 0.74‐0.98) | Insignificant difference |
| Wactawski‐Wende31 | 168/18 716 | 154/18 106 | Negative (RR, 1.08; 95% CI, 0.86‐1.34) | Insignificant difference |
| aBaron32 | 345/762 | 362/761 | Negative (RR, 0.91; 95% CI, 0.75‐1.12) | Insignificant difference |
| 438/1024 | 442/1035 | Negative (RR, 1.00; 95% CI, 0.84‐1.19) | Insignificant difference | |
| Pommergaard33 | 52/209 | 58/218 | Negative (RR, 0.95; 95% CI, 0.61‐1.48) | Insignificant difference |
Abbreviations: 95% CI, 95% confidence interval; CRC, colorectal cancer; RCT, randomized controlled trial; RR, relative risk.
a
Study included in a meta‐analysis.